Clinical Trial Update: Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a triplet regimen of zanubrutinib, obinutuzumab, and lenalidomide (ZGR) in high-risk, treatment-naive follicular lymphoma; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Ruijin Hospital | Conditions: Follicular Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING